Almost two years after finally pulling the plug on a big non-opioid painkiller programme, Eli Lilly has ... royalty rate. Lilly’s last attempt to develop a non-opioid pain drug was with Pfizer ...
Eli Lilly’s new chief executive David Ricks has made his first acquisition, bringing in biotech CoLucid for $960 million – reacquiring a migraine drug the big pharma sold off 12 years ago.
Eli Lilly wants to take big swings in Alzheimer’s, ALS, chronic pain and other difficult diseases after its success in ...
While Novo Nordisk's Ozempic is the most mainstream GLP-1 medication, Eli Lilly (NYSE: LLY) has two blockbuster weight loss drugs of its own: Mounjaro and Zepbound. Mounjaro and Zepbound are by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results